JP2024505143A5 - - Google Patents
Info
- Publication number
- JP2024505143A5 JP2024505143A5 JP2023541948A JP2023541948A JP2024505143A5 JP 2024505143 A5 JP2024505143 A5 JP 2024505143A5 JP 2023541948 A JP2023541948 A JP 2023541948A JP 2023541948 A JP2023541948 A JP 2023541948A JP 2024505143 A5 JP2024505143 A5 JP 2024505143A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- dosage form
- pharmaceutical dosage
- oral pharmaceutical
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2100352.0 | 2021-01-12 | ||
| GBGB2100352.0A GB202100352D0 (en) | 2021-01-12 | 2021-01-12 | New methods |
| PCT/GB2022/050054 WO2022153042A1 (en) | 2021-01-12 | 2022-01-11 | 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505143A JP2024505143A (ja) | 2024-02-05 |
| JP2024505143A5 true JP2024505143A5 (https=) | 2025-02-21 |
Family
ID=74667674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541948A Pending JP2024505143A (ja) | 2021-01-12 | 2022-01-11 | 医薬における使用のための４－クロロ－ｎ－［２－［（４－クロロフェニル）メチル］－３－オキソ－１，２，４－チアジアゾール－５－イル］ベンズアミド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240082222A1 (https=) |
| EP (1) | EP4277625A1 (https=) |
| JP (1) | JP2024505143A (https=) |
| KR (1) | KR20230159375A (https=) |
| CN (1) | CN117320716A (https=) |
| AU (1) | AU2022208237A1 (https=) |
| BR (1) | BR112023013828A2 (https=) |
| CA (1) | CA3208099A1 (https=) |
| GB (1) | GB202100352D0 (https=) |
| IL (1) | IL304392A (https=) |
| MX (1) | MX2023008263A (https=) |
| WO (1) | WO2022153042A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| WO2025027205A1 (en) * | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) * | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| AU2011281381B2 (en) * | 2010-07-21 | 2015-07-16 | Novartis Ag | Salt and solvates of a tetrahydroisoquinoline derivative |
| KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| US11691954B2 (en) * | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
-
2021
- 2021-01-12 GB GBGB2100352.0A patent/GB202100352D0/en not_active Ceased
-
2022
- 2022-01-11 JP JP2023541948A patent/JP2024505143A/ja active Pending
- 2022-01-11 EP EP22701013.9A patent/EP4277625A1/en active Pending
- 2022-01-11 US US18/271,627 patent/US20240082222A1/en active Pending
- 2022-01-11 MX MX2023008263A patent/MX2023008263A/es unknown
- 2022-01-11 CN CN202280020127.2A patent/CN117320716A/zh active Pending
- 2022-01-11 BR BR112023013828A patent/BR112023013828A2/pt unknown
- 2022-01-11 AU AU2022208237A patent/AU2022208237A1/en active Pending
- 2022-01-11 CA CA3208099A patent/CA3208099A1/en active Pending
- 2022-01-11 WO PCT/GB2022/050054 patent/WO2022153042A1/en not_active Ceased
- 2022-01-11 KR KR1020237027428A patent/KR20230159375A/ko active Pending
-
2023
- 2023-07-11 IL IL304392A patent/IL304392A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2024505143A5 (https=) | ||
| CN110051638B (zh) | 包含双胍的延迟释放组合物 | |
| JP2021504423A5 (https=) | ||
| CN110693867A (zh) | 用于治疗代谢性病症的组合物和方法 | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| TW201125874A (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| JP5698682B2 (ja) | トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途 | |
| CA3014411A1 (en) | Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer | |
| EP0078079B1 (en) | Nitrofurantoin dosage form | |
| JP2022529208A5 (https=) | ||
| TW200817000A (en) | New paediatric indications for direct thrombin inhibitors | |
| EP2435052B1 (en) | Solid oral dosage forms of lamivudine with isomalt | |
| WO2023228023A1 (en) | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| CN113350325B (zh) | 二蒽酮类化合物在制备抗肿瘤药物中的应用 | |
| BR112020017056A2 (pt) | Composição farmacêutica compreendendo remogliflozina e um agente antidiabético | |
| CA2470342C (en) | Ribavirin granulate for producing coated tablets | |
| CN110623955A (zh) | Wnk激酶抑制剂在预防和/或治疗高原病中的用途 | |
| JP7848121B2 (ja) | 感冒剤及び抗ウイルス剤 | |
| US20210346506A1 (en) | Prodrug of itraconazole and uses thereof | |
| TR2023007202A1 (tr) | Saksagli̇pti̇n, pi̇ogli̇tazon ve bi̇r sglt-2 i̇nhi̇bi̇törü i̇çeren bi̇r farmasöti̇k formülasyon | |
| WO2025099561A1 (en) | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2024506336A (ja) | 膠芽腫の治療方法 | |
| HK40021394A (en) | Compositions and methods for treating metabolic disorders | |
| HK40012109B (zh) | 包含双胍的延迟释放组合物 |